{'Year': '2018', 'Month': 'May'}
Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.
A tailored antiplatelet strategy based on CYP2C19 genotype may reduce atherothrombotic and bleeding events. We describe our experience with CYP2C19 genotyping, using on-site TaqMan or Spartan genotyping or shipment to a central laboratory.